Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Welcure Drugs & Pharmaceuticals Ltd

₹ 0.390.00%
16 Jan – close price
🔗Company website•BSE: 524661•NSE:
Market Cap₹ 48.2 Cr.
Current Price₹ 0.39
High / Low₹ 1.45
Stock P/E1.40
Book Value₹ 1.09
Dividend Yield0.00 %
ROCE2.53 %
ROE4.18 %
Face Value₹ 1.00
Sales₹ 388 Cr.
OPM11.2 %
Mar Cap₹ 48.2 Cr.

ABOUT

Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]

KEY POINTS

Business Overview:[1]WDPL is engaged in the manufacture andtrade of a wide range of healthcare formulations.

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsPreferential IssuanceOrder Book PositionLarge Order ReceiptsJv Partnerships AcquisitionsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1668.9034.69400460.330.963124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1512.970.07
2.Divi's Lab.6236.0066.61165513.660.48689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7413.530.01
3.Torrent Pharma.4018.2062.75135955.090.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1013.260.33
4.Cipla1397.5020.75112878.160.931353.373.737589.447.6422.7228349.5725.405441.141351.173.4314.720.01
5.Lupin2177.9023.0199527.000.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0712.410.32
6.Dr Reddy's Labs1175.5017.0098114.930.681336.807.288828.309.8322.6934310.0024.645772.201347.102.7212.950.16
7.Mankind Pharma2175.4051.3789821.630.05520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.878.890.55
8.Welcure Drugs0.391.4048.200.008.50361.9665.62167.292.53387.6211.1634.388.500.361.620.92
–Median: 149 Co.392.630.01767.160.1213.9610.46161.7610.5814.89603.8515.9345.2614.123.138.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
0.000.000.000.000.000.000.000.0024.550.8821.21299.9165.62
Expenses
0.020.010.050.030.090.060.060.3422.710.7920.57268.7754.25
Operating Profit
-0.02-0.01-0.05-0.03-0.09-0.06-0.06-0.341.840.090.6431.1411.37
Other Income
0.010.010.220.000.000.040.060.000.000.001.910.000.00
Profit before tax
-0.010.000.17-0.03-0.10-0.03-0.02-0.341.830.092.5431.1411.37
Tax %
0.00%–0.00%0.00%0.00%0.00%0.00%0.00%0.00%55.56%0.00%25.18%25.15%
Net Profit
-0.010.000.17-0.03-0.10-0.03-0.02-0.341.840.042.5423.308.50
EPS in Rs
-0.000.000.01-0.00-0.01-0.00-0.00-0.020.010.000.020.190.07

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
0000000000025388
Expenses
0000000000024344
Operating Profit
-0000-00-000-0-0143
Other Income
0000000000022
Interest
0000000000000
Depreciation
0000000000000
Profit before tax
0000-00-0000-0345
Net Profit
0000-00-0000-0234
EPS in Rs
0.000.000.010.00-0.000.00-0.000.000.000.01-0.010.020.28
Dividend Payout %
–0%0%0%0%–0%0%0%0%0%0%–

Compounded Sales Growth

10 Years:86%
5 Years:214%
3 Years:507%
TTM:1479%

Compounded Profit Growth

10 Years:71%
5 Years:194%
3 Years:377%
TTM:2271%

Stock Price CAGR

10 Years:3%
5 Years:13%
3 Years:-6%
1 Year:-59%

Return on Equity

10 Years:%
5 Years:4%
3 Years:4%
Last Year:4%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
1212121212121212121313112112
Reserves
-12-12-12-12-12-12-12-12-12-12-12-1022
Borrowings
00000000000123123
Other Liabilities
0000000000041375
Total Liabilities
00000000021267633
Fixed Assets
0000000000000
Gross Block
0.000.000.000.000.000.000.000.000.000.060.060.08–
Accumulated Depreciation
0.000.000.000.000.000.000.000.000.000.000.040.05–
CWIP
0000000000000
Investments
0000000000000
Other Assets
00000000011267633
Total Assets
00000000021267633

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
00-00-00-0000-0-222
Cash from Investing Activity
-00000000000-0
Cash from Financing Activity
000000000-0-0222
Net Cash Flow
-00-00-00-000-000

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
000000000––282
Inventory Days
–––––––––––2,554
Days Payable
–––––––––––52
Cash Conversion Cycle
000000000––2,784
Working Capital Days
-1,186-87636817346000––2,092
ROCE %
–––120%-67%0%-40%133%25%10%-13%3%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
–––––––––––––
FIIs
–––––––––––––
DIIs
0.01%0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public
99.99%99.99%100.00%100.00%99.99%100.00%100.00%100.00%100.00%99.98%99.99%99.99%100.00%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Welcure Drugs Submits SEBI Compliance Certificate for Q4 FY26; No Physical Shares Received for Dematerialization

3rd April 2026, 9:00 pm

Welcure Drugs to Close Trading Window from April 1, 2026

26th March 2026, 8:39 pm

Welcure Drugs & Pharmaceuticals Publishes 3rd Quarter Unaudited Financial Results

14th February 2026, 6:23 pm

Welcure Drugs & Pharmaceuticals: Board Approves Unaudited Q3 FY26 Financial Results with Significant YoY Revenue and Profit Growth

13th February 2026, 1:06 am

Welcure Drugs & Pharma Reports Explosive YoY Q3 FY26 Results Driven by Agriculture Segment Pivot

13th February 2026, 12:56 am

Published by Other Websites

External media mentions & references

Indian Market Cap Soars Past Rs 473 Lakh Crore! Sensex, Nifty Edge Higher - Don't Miss This Crucial Update!

13th November 2025, 4:49 pm

14 Indian Stocks Including TCS to Trade Ex-Date for Dividends, Splits, Rights & Bonus Issues This Week

10th October 2025, 2:59 pm

Welcure Board Approves Stake Purchase by Telexcell Without Control Rights

29th September 2025, 4:49 pm

Welcure Board Considers 25% Stake Sale to Telexcell, Rejects Management Control Bid

29th September 2025, 4:12 pm

Singapore's Telexcell Trade to Buy 25% Stake in Welcure Drugs for Rs 52 Crore

4th September 2025, 12:05 pm

News Articles

Editorial & research coverage

Indian Market Cap Soars Past Rs 473 Lakh Crore! Sensex, Nifty Edge Higher - Don't Miss This Crucial Update!
Indian Market Cap Soars Past Rs 473 Lakh Crore! Sensex, Nifty Edge Higher - Don't Miss This Crucial Update!

13th November 2025, 4:49 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

5 Jan - Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the 3rd Quarter ended 31st December, 2025.

Closure of Trading Window
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Welcure Drugs And Pharmaceuticals Limited Held Today I.E. Saturday, December 06, 2025

6 Dec 2025 - Board recognised ₹299.91 crore domestic sales; ~₹517 crore mandate discontinued; multiple deal aborts (06 Dec 2025).

Postponement Of The Meeting Of The Rights Issue Committee Of Welcure Drugs And Pharmaceuticals Limited Which Was To Be Held Today I.E. Monday, December 05, 2025

5 Dec 2025 - Rights Issue Committee meeting scheduled Dec 05, 2025 postponed pending stock exchange in-principle approval.

Board Meeting Intimation for Intimation Of Rights Issue Committee Meeting To Be Held On 05Th December, 2025 For Deciding Issue Price And Other Terms Of The Rights Issue

1 Dec 2025 - Board approved rights issue up to Rs.49,00,00,000; Rights Committee meets 05-Dec-2025 to fix price.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

No credit ratings.

Concalls

No concalls.

Stock Analysis

Description

  1. Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.

Key Growth Triggers

  1. Currently no data available for Key Growth Triggers.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. The company has repeatedly received a Disclaimer of Opinion from its statutory auditor in its recent financial results (Q2/H1 FY26) due to significant concerns regarding financial documentation, inventory valuation, and unconfirmed balances, indicating severe transparency issues that warrant close investor scrutiny.

Key Dates To Watch

  1. Currently no data available for Key Dates To Watch.

Corporate Announcements

3rd Apr 26
Impact Rating: 4
Welcure Drugs & Pharmaceuticals Ltd. has filed its SEBI compliance certificate for the year ended March 31, 2026, stating that its registrar confirmed no physical share certificates were received for dematerialization.
26th Mar 26
Impact Rating: 7
In compliance with SEBI regulations, Welcure Drugs and Pharmaceuticals Limited will close its trading window for designated persons and their relatives from April 1, 2026. This restriction lasts until 48 hours after the announcement of audited standalone Q4 and annual financial results for the year ended March 31, 2026.
14th Feb 26
Impact Rating: -
No description available.
12th Feb 26
Impact Rating: 5
Welcure Drugs & Pharmaceuticals board approved Q3 FY26 unaudited financials. Revenue jumped 642% YoY to ₹65.62 Cr, PAT surged 1950% YoY to ₹8.51 Cr. Nine-month figures also show robust growth. Segmental revenue dominance shifted from Pharma in FY25 to Agriculture in FY26.
12th Feb 26
Impact Rating: 7
Welcure Drugs' Q3 FY26 results show significant YoY revenue and profit surge, driven by a pivot to its Agriculture segment.